Young-Suk Lim Selected Research

Infections

2/2024	Safety, pharmacodynamics, and antiviral activity of selgantolimod in viremic patients with chronic hepatitis B virus infection.
11/2023	Are the New Nucleos(t)ide Analogs Better than the Old Nucleos(t)ide Analogs?
10/2023	Evaluation of RNAi therapeutics VIR-2218 and ALN-HBV for chronic hepatitis B: Results from randomized clinical trials.
8/2023	Long-term Treatment With Tenofovir Alafenamide for Chronic Hepatitis B Results in High Rates of Viral Suppression and Favorable Renal and Bone Safety.
1/2023	Prediction of Hepatocellular Carcinoma Development in Korean Patients after Hepatitis C Cure with Direct-Acting Antivirals.
1/2023	Efficacy and safety of sofosbuvir-velpatasvir and sofosbuvir-velpatasvir-voxilaprevir for hepatitis C in Korea: a Phase 3b study.
1/2023	New biomarkers of hepatitis B virus (HBV) infection: HBV RNA and HBV core-related antigen, new kids on the block?
12/2022	Hepatitis B Virus Treatment and Hepatocellular Carcinoma: Controversies and Approaches to Consensus.
12/2022	Safety, pharmacokinetics, and antiviral activity of the capsid inhibitor AB-506 from Phase 1 studies in healthy subjects and those with hepatitis B.
1/2022	A risk scoring system to predict clinical events in chronic hepatitis B virus infection: A nationwide cohort study.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Young-Suk Lim Research Topics

Disease

116	Hepatocellular Carcinoma (Hepatoma) 04/2024 - 06/2008
82	Chronic Hepatitis B 04/2024 - 08/2004
34	Neoplasms (Cancer) 11/2023 - 05/2008
32	Infections 02/2024 - 06/2006
31	Fibrosis (Cirrhosis) 02/2024 - 10/2002
15	Hepatitis B 11/2023 - 06/2006
13	Liver Diseases (Liver Disease) 05/2024 - 10/2005
12	Liver Neoplasms (Liver Cancer) 04/2024 - 11/2013
8	Chronic Hepatitis C 01/2023 - 03/2013
7	Liver Cirrhosis (Hepatic Cirrhosis) 01/2022 - 06/2011
6	End Stage Liver Disease 12/2023 - 10/2005
5	Acute Liver Failure (Fulminant Hepatic Failure) 01/2018 - 01/2010
5	Non-alcoholic Fatty Liver Disease 08/2016 - 05/2010
5	Thrombosis (Thrombus) 03/2015 - 09/2010
4	Hepatitis 02/2024 - 06/2006
4	Hepatic Encephalopathy 09/2023 - 03/2008
4	Cholangiocarcinoma 08/2023 - 01/2018
4	Neoplasm Metastasis (Metastasis) 09/2022 - 03/2010
3	Esophageal and Gastric Varices (Esophageal Varices) 09/2023 - 01/2012
3	Hepatitis C 01/2023 - 06/2010
3	Respiratory Tract Infections (Respiratory Tract Infection) 01/2020 - 11/2016
3	Nasopharyngitis 01/2020 - 11/2016
3	Ascites 01/2020 - 10/2002
2	Inflammation (Inflammations) 10/2023 - 01/2018
2	Hemorrhage 09/2023 - 01/2022
2	Disease Progression 01/2023 - 04/2021
2	Viremia 01/2023 - 10/2018
2	Fatty Liver 01/2020 - 08/2016
2	Autoimmune Hepatitis 01/2019 - 01/2008
2	Hepatitis E 10/2018 - 09/2011
2	Hepatitis A (Hepatitis, Infectious) 01/2018 - 12/2012
2	Headache (Headaches) 11/2016 - 11/2016
2	Necrosis 11/2015 - 03/2013
1	Unstable Angina 11/2023
1	Ischemic Stroke 11/2023
1	Heart Failure 11/2023
1	Myocardial Infarction 11/2023
1	Cardiovascular Diseases (Cardiovascular Disease) 10/2023

Drug/Important Bio-Agent (IBA)

36	Tenofovir (Viread)FDA Link 01/2024 - 01/2016
35	Antiviral Agents (Antivirals)IBA 02/2024 - 08/2004
35	entecavir FDA Link 01/2024 - 10/2009
22	DNA (Deoxyribonucleic Acid)IBA 02/2024 - 09/2011
17	Alanine Transaminase (SGPT)IBA 05/2024 - 05/2010
17	Hepatitis B e AntigensIBA 04/2024 - 08/2004
15	tenofovir alafenamideIBA 02/2024 - 11/2016
14	Hepatitis B Surface Antigens (HBsAg)FDA Link 02/2024 - 06/2006
12	Lamivudine (Epivir)FDA Link 11/2019 - 08/2004
10	Sorafenib (BAY 43-9006)FDA Link 04/2021 - 11/2011
10	alpha-Fetoproteins (alpha-Fetoprotein)IBA 01/2020 - 03/2010
9	gadolinium ethoxybenzyl DTPA FDA Link 12/2022 - 04/2015
9	adefovirIBA 01/2019 - 06/2006
8	Biomarkers (Surrogate Marker)IBA 01/2023 - 01/2016
6	Fetal Proteins (Fetoprotein)IBA 01/2023 - 07/2012
4	CholesterolIBA 10/2023 - 08/2012
4	CreatinineIBA 11/2016 - 04/2010
4	Ribavirin (Virazole)FDA LinkGeneric 11/2016 - 06/2010
3	Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)IBA 11/2023 - 11/2021
3	AntigensIBA 01/2023 - 09/2011
3	InterferonsIBA 12/2022 - 01/2018
3	Serum AlbuminIBA 10/2021 - 05/2015
3	NucleosidesIBA 08/2014 - 09/2011
3	Immunoglobulins (Immunoglobulin)IBA 04/2011 - 06/2006
3	hepatitis B hyperimmune globulinIBA 04/2011 - 06/2006
3	adefovir dipivoxil (Hepsera)FDA Link 06/2006 - 08/2004
2	selgantolimodIBA 02/2024 - 10/2021
2	AlbuminsIBA 01/2023 - 11/2020
2	SofosbuvirIBA 01/2023 - 12/2018
2	RNA (Ribonucleic Acid)IBA 01/2023 - 11/2022
2	nasIBA 12/2022 - 01/2022
2	Tumor Biomarkers (Tumor Markers)IBA 08/2022 - 11/2021
2	ProteomeIBA 08/2022 - 05/2020
2	Iodized OilIBA 02/2022 - 03/2013
2	HDL CholesterolIBA 01/2022 - 01/2012
2	NivolumabIBA 07/2020 - 07/2020
2	Gemcitabine FDA Link 11/2018 - 01/2018
2	Cisplatin (Platino)FDA LinkGeneric 11/2018 - 01/2018
2	Immunosuppressive Agents (Immunosuppressants)IBA 11/2017 - 11/2012
2	Interferon-alpha (Interferon Alfa)IBA 11/2016 - 08/2004
2	ORALIT (ORS)IBA 11/2015 - 10/2015
2	Ethiodized Oil (Ethiodol)FDA Link 06/2013 - 03/2013
2	Immunoglobulin M (IgM)IBA 12/2012 - 06/2006
2	Proteins (Proteins, Gene)FDA Link 01/2012 - 02/2011
1	omega-Chloroacetophenone (Mace)IBA 11/2023
1	LipidsIBA 10/2023
1	HDL LipoproteinsIBA 10/2023
1	Immune Checkpoint InhibitorsIBA 08/2023
1	velpatasvirIBA 01/2023

Therapy/Procedure

49	Therapeutics 02/2024 - 08/2004
26	Liver Transplantation 04/2024 - 03/2008
17	Radiotherapy 03/2023 - 05/2009
6	Transplantation 01/2021 - 06/2011
5	Radiofrequency Ablation 07/2021 - 12/2013
5	Hepatectomy 01/2021 - 03/2010
4	Drug Therapy (Chemotherapy) 01/2022 - 01/2016
3	Salvage Therapy 02/2022 - 01/2012
3	Immunotherapy 01/2022 - 06/2015
3	Conformal Radiotherapy 01/2015 - 09/2010
2	Surgical Portasystemic Shunt (Portosystemic Shunt) 09/2023 - 03/2008
2	Aftercare (After-Treatment) 01/2015 - 06/2008
1	RNAi Therapeutics 10/2023